Option
CEUS Reporting Template Sample: Liver
Procedure: [Contrast Enhanced Ultrasound– (date)]
History: [Risk factor, surgical and medical history]
Indication: [nodule or observation on prior imaging requiring further characterization]
Comparison: [Include modality and date]
Technique: [Real-time ultrasound evaluation of [focal liver observation/other indication] was
performed before and after microbubble contrast agent administration, with representative
images obtained for documentation.] Examination quality is [appropriate in accordance with
[ACR-AIUM-SRU Practice Parameter technical recommendations.] [is compromised by the
following factor(s): ().]
Intravenous contrast agent:
Number of injections [ ] x [ ] ml. [ ] vial of [name of the contrast agent] was used and the rest
was discarded.
[Adverse events:]
Findings:
Quality of the study: include greyscale and CEUS as independent evaluations
Observation #: 1/2/3/4/5
Distinct nodule: [Yes/No]
Location: Segment I/II/III/IVa/IVb/V/VI/VII/VIII or lobe right/left
Size: [ ] x [ ] [mm/cm]
AP Hyperenhancement: [Yes/No] [whole/in part/mosaic/nodule in nodule/rim/peripheral
discontinuous globular/other]
Washout: [Yes/No] [early/late] [mild/marked] washout seen at approximately [ ] s/m
Hepatic vasculature: [patency, any abnormal findings if applicable]
[Other findings (optional)]
Impression:
[summary of CEUS findings, and recommendation or “no observation on non-contrast US. CEUS
was not performed”]
[additional findings as above, or summary]
Option
2
CEUS Reporting Template Sample: generic
Procedure: [Contrast Enhanced Ultrasound– (date)]
History: [Risk factor, surgical and medical history]
Indication: [nodule or observation on prior imaging requiring further characterization/or other
indication]
Comparison: [Include modality and date]
Technique: [Real-time ultrasound evaluation of [focal liver observation/other indication] was
performed before and after microbubble contrast agent administration, with representative
images obtained for documentation.]
Examination quality is [appropriate in accordance with [ACR-AIUM-SRU Practice Parameter
technical recommendations.] [is compromised by the following factor(s): ().]
Intravenous contrast agent:
Number of injections [ ] x [ ] ml. [ ] vial of [name of the contrast agent] was used and the rest
was discarded.
[Adverse events:]
Findings:
Quality of the study: include greyscale and CEUS as independent evaluations
• For liver observation/nodule characterization on patients at risk for HCC (cirrhosis of any
etiology and chronic HBV with or without cirrhosis), use CEUS LI-RADS template.
• For liver observation/nodule characterization on patients not at risk for HCC describe
location, size, assessment of arterial phase/degree and pattern of enhancement,
presence of washout/timing and degree if washout, and overall impression.
• For kidney observation/nodule, describe location, size, assessment of arterial phase
/degree and pattern of enhancement, presence of washout, and overall impression.
• For other indications, describe the CEUS findings and your impression.
Impression:
[summary of CEUS findings, and recommendation or “no observation on non-contrast US. CEUS
was not performed”]
[additional findings as above, or summary]
